RaDaR MRD testing is validated for use in multiple solid tumor cancers
HEAD & NECK CANCER
Liquid biopsies allow for real-time tumor analysis from a single blood sample
- A liquid biopsy is a blood test that detects signs of cancerous tumors after diagnosis, such as circulating tumor DNA (ctDNA)
- ctDNA are short fragments of DNA that get released into the bloodstream from tumor cells
- Liquid biopsy tests can provide powerful insights into a patient’s tumor and offer several advantages over traditional tissue-based biopsies:
- Easy to perform and minimally invasive, requiring only a blood draw
- Offer a real-time snapshot of a patient’s tumor
- Repeat testing can be performed, allowing a patient’s disease to be tracked over time
MRD is a very small number of cancer cells that remain in the body during or after treatment
Minimal residual disease (MRD), also known as molecular residual disease, refers to the trace amounts of cancer remaining in a patient’s body after curative-intent treatment or that can be found as a patient’s tumor recurs. MRD can be detected by using minimally invasive liquid biopsy tests, which search for circulating tumor DNA (ctDNA) in a patient’s blood sample. MRD tests, such as RaDaR, are able to detect tumor DNA much earlier, and with greater sensitivity, than conventional monitoring tests or radiographic scans.1-3
MRD tests enable quicker, more confident decision-making
MRD tests help answer key questions across the cancer care continuum
- Neoadjuvant period: Is the patient responding to neoadjuvant therapy? What is the patient’s prognosis?
- Post-curative-intent treatment: Does the patient have residual disease? Is the patient at high risk for relapse? Would the patient benefit from adjuvant therapy? Should a clinical trial be considered for the patient?
- Surveillance: Is the patient still in remission? Is the patient’s cancer coming back?
RaDaR is a personalized test for minimal residual disease (MRD) and recurrence detection
RaDaR has been carefully designed to detect tumor DNA in the blood with exceptional sensitivity and specificity
- Increased accuracy with a tumor-informed, personalized panel design: RaDaR sequencing assays monitor up to 48 tumor-specific mutations, unique to each patient’s tumor, to help detect circulating tumor DNA (ctDNA)
- Earlier detection with high sensitivity: RaDaR can detect extremely low levels of ctDNA in the blood, with a demonstrated LoD95 = 0.001% VAF. This can give additional time for important treatment management decisions
- Fewer false positives with high specificity: RaDaR has a demonstrated analytical specificity of 100% in validation studies for more reliable results
NeoGenomics has been supporting oncologists and pathologists in their goal to provide patients with the best care possible since 2002.
LoD95 = limit of detection, working at a confidence of 95%; VAF = variant allele fraction.
How does RaDaR work?
Send in a patient’s formalin-fixed paraffin-embedded (FFPE) tumor sample to the NeoGenomics laboratory
Patient’s tumor DNA is sequenced to determine their tumor’s unique mutation profile
A personalized RaDaR panel is designed for the patient
After initial panel design, ctDNA is tested using blood samples and the patient’s custom RaDaR panel
Report is generated
How to order a RaDaR test
NeoGenomics prides itself on its unparalleled customer support team. If you have questions regarding test information, specimen requirements, turnaround times, test add-on, and test results, please feel free to reach out to a Client Services Advocate at email@example.com or call 866.776.5907, option 3.
Online Ordering streamlines and simplifies your test-ordering process into a single time-saving, easy-to-use experience.
PAPER ORDER FORMS
Complete a RaDaR test requisition form.
New to NeoGenomics? Call the NeoGenomics Client Services team at 866.776.5907 and press 3 to set up an account.
* The analytical validation study of RaDaR demonstrates a limit of detection (LoD95) of 0.001% variant allele fraction (VAF) with 100% specificity.
References: 1. Tie J, et al. Sci Transl Med. 2016;8(346):346ra92. doi:10.1126/scitranslmed.aaf6219. 2. Chakrabarti S, et al. Cancers. 2020;12(10):2808-2826. 3. Dasari A, Nat Rev Clin Oncol. 2020;17:757-770.
Get started with RaDaR
Contact us to order a RaDaR test.